Current issue
Archive
Manuscripts accepted
About the Journal
Editorial office
Editorial board
Abstracting and indexing
Subscription
Contact
Ethical standards and procedures
Most read articles
Instructions for authors
Article Processing Charge (APC)
Regulations of paying article processing charge (APC)
ONCOLOGY / BASIC RESEARCH
Causal associations between blood metabolites and breast cancer
1
Department of Pathology, Affiliated Cancer Hospital of Harbin Medical University, Nangang, Harbin, Heilongjiang, China
2
Department of Colorectal Cancer Surgery, Affiliated Cancer Hospital of Harbin Medical University, Nangang, Harbin, Heilongjiang, China
Submission date: 2024-02-06
Final revision date: 2024-04-12
Acceptance date: 2024-05-04
Online publication date: 2024-06-07
Publication date: 2025-02-28
Corresponding author
Chun Du
Department of Pathology Affiliated Cancer Hospital of Harbin Medical University No. 157, Health Road Nangang, Harbin 150081 Heilongjiang, China
Department of Pathology Affiliated Cancer Hospital of Harbin Medical University No. 157, Health Road Nangang, Harbin 150081 Heilongjiang, China
Arch Med Sci 2025;21(1):206-214
KEYWORDS
TOPICS
ABSTRACT
Introduction:
The associations between blood metabolites and breast cancer remain unclear. We conducted a systematic two-sample Mendelian randomization (MR) analysis to identify key human blood metabolites and potential biomarkers for breast cancer development.
Material and methods:
The data were extracted from large-scale genome-wide association study (GWAS) public databases. Instrumental variables were selected from a cohort study of 453 metabolic profiles from 7,824 participants. Breast cancer incidence data were obtained from a large cohort study involving 138,389 cases and 240,341 controls. Causal associations between human blood metabolites and breast cancer incidence were assessed using inverse-variance weighting, and MR-Egger regression.
Results:
Five human blood metabolites were identified as biomarkers for breast cancer: serine (OR = 2.25; 95% CI: 1.18–4.27), 10-undecenoate (11:1n1) (OR = 1.38; 95% CI: 1.00–1.90), X-12696 (OR = 2.15; 95% CI: 1.14–4.08), X-14626 (OR = 1.68; 95% CI: 1.15–2.46), and succinyl carnitine (OR = 1.58; 95% CI: 1.06–2.34). The sensitivity analysis results indicate no pleiotropy between the metabolites and breast cancer risk, confirming the robustness of the findings.
Conclusions:
This study in metabolomics research identified five human blood metabolites – serine, 10-undecenoate (11:1n1), X-12696, X-14626, and succinylcarnitine – as potential biomarkers for assessing breast cancer risk. Among these metabolites, serine and X-12696 showed the strongest associations with the likelihood of developing breast cancer.
The associations between blood metabolites and breast cancer remain unclear. We conducted a systematic two-sample Mendelian randomization (MR) analysis to identify key human blood metabolites and potential biomarkers for breast cancer development.
Material and methods:
The data were extracted from large-scale genome-wide association study (GWAS) public databases. Instrumental variables were selected from a cohort study of 453 metabolic profiles from 7,824 participants. Breast cancer incidence data were obtained from a large cohort study involving 138,389 cases and 240,341 controls. Causal associations between human blood metabolites and breast cancer incidence were assessed using inverse-variance weighting, and MR-Egger regression.
Results:
Five human blood metabolites were identified as biomarkers for breast cancer: serine (OR = 2.25; 95% CI: 1.18–4.27), 10-undecenoate (11:1n1) (OR = 1.38; 95% CI: 1.00–1.90), X-12696 (OR = 2.15; 95% CI: 1.14–4.08), X-14626 (OR = 1.68; 95% CI: 1.15–2.46), and succinyl carnitine (OR = 1.58; 95% CI: 1.06–2.34). The sensitivity analysis results indicate no pleiotropy between the metabolites and breast cancer risk, confirming the robustness of the findings.
Conclusions:
This study in metabolomics research identified five human blood metabolites – serine, 10-undecenoate (11:1n1), X-12696, X-14626, and succinylcarnitine – as potential biomarkers for assessing breast cancer risk. Among these metabolites, serine and X-12696 showed the strongest associations with the likelihood of developing breast cancer.
REFERENCES (33)
1.
Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2021; 71: 209-49.
2.
Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer Statistics, 2021. CA Cancer J Clin 2021; 71: 7-33.
3.
Key TJ, Appleby PN, Reeves GK, Roddam AW. Insulin-like growth factor 1 (IGF1), IGF binding protein 3 (IGFBP3), and breast cancer risk: pooled individual data analysis of 17 prospective studies. Lancet Oncol 2010; 11: 530-42.
4.
Li Y, Sundquist K, Zhang N, Wang X, Sundquist J, Memon AA. Mitochondrial related genome-wide Mendelian randomization identifies putatively causal genes for multiple cancer types. EBioMedicine 2023; 88: 104432.
5.
Zhu M, Ma Z, Zhang X, et al. C-reactive protein and cancer risk: a pan-cancer study of prospective cohort and Mendelian randomization analysis. BMC Med 2022; 20: 301.
6.
Ussher JR, Elmariah S, Gerszten RE, Dyck JR. The emerging role of metabolomics in the diagnosis and prognosis of cardiovascular disease. J Am Coll Cardiol 2016; 68: 2850-70.
7.
Swerdlow DI, Kuchenbaecker KB, Shah S, et al. Selecting instruments for Mendelian randomization in the wake of genome-wide association studies. Int J Epidemiol 2016; 45: 1600-16.
8.
Yun Z, Guo Z, Li X, et al. Genetically predicted 486 blood metabolites in relation to risk of colorectal cancer: a Mendelian randomization study. Cancer Med 2023; 12: 13784-99.
9.
Emdin CA, Khera AV, Kathiresan S. Mendelian randomization. JAMA 2017; 318: 1925-6.
10.
Hartwig FP, Davies NM, Hemani G, Davey Smith G. Two-sample Mendelian randomization: avoiding the downsides of a powerful, widely applicable but potentially fallible technique. Int J Epidemiol 2016; 45: 1717-26.
11.
Shin SY, Fauman EB, Petersen AK, et al. An atlas of genetic influences on human blood metabolites. Nat Genet 2014; 46: 543-50.
13.
Sakaue S, Kanai M, Tanigawa Y, et al. A cross-population atlas of genetic associations for 220 human phenotypes. Nat Genet 2021; 53: 1415-24.
14.
Hemani G, Zheng J, Elsworth B, et al. The MR-Base platform supports systematic causal inference across the human phenome. eLife 2018; 7: e34408.
15.
Burgess S, Butterworth A, Thompson SG. Mendelian randomization analysis with multiple genetic variants using summarized data. Genet Epidemiol 2013; 37: 658-65.
16.
Bowden J, Davey Smith G, Haycock PC, Burgess S. Consistent estimation in mendelian randomization with some invalid instruments using a weighted median estimator. Genet Epidemiol 2016; 40: 304-14.
17.
Burgess S, Thompson SG. Interpreting findings from Mendelian randomization using the MR-Egger method. Eur J Epidemiol 2017; 32: 377-89.
18.
Ye J, Fan J, Venneti S, et al. Serine catabolism regulates mitochondrial redox control during hypoxia. Cancer Discov 2014; 4: 1406-17.
19.
Labuschagne CF, van den Broek NJ, Mackay GM, Vousden KH, Maddocks OD. Serine, but not glycine, supports one-carbon metabolism and proliferation of cancer cells. Cell Rep 2014; 7: 1248-58.
20.
Wilcz-Villega E, Carter E, Ironside A, et al. Macrophages induce malignant traits in mammary epithelium via IKK/TBK1 kinases and the serine biosynthesis pathway. EMBO Mol Med 2020; 12: e10491.
21.
Kim HY, Lee KM, Kim SH, Kwon YJ, Chun YJ, Choi HK. Comparative metabolic and lipidomic profiling of human breast cancer cells with different metastatic potentials. Oncotarget 2016; 7: 67111-28.
22.
Yang M, Vousden KH. Serine and one-carbon metabolism in cancer. Nat Rev Cancer 2016; 16: 650-62.
23.
Fan J, Teng X, Liu L, et al. Human phosphoglycerate dehydrogenase produces the oncometabolite D-2-hydroxyglutarate. ACS Chem Biol 2015; 10: 510-6.
24.
van der Spek A, Stewart ID, Kühnel B, et al. Circulating metabolites modulated by diet are associated with depression. Mol Psychiatry 2023; 28: 3874-87.
25.
Puri P, Baillie RA, Wiest MM, et al. A lipidomic analysis of nonalcoholic fatty liver disease. Hepatology 2007; 46: 1081-90.
26.
De Cicco P, Catani MV, Gasperi V, Sibilano M, Quaglietta M, Savini I. Nutrition and breast cancer: a literature review on prevention, treatment and recurrence. Nutrients 2019; 11: 1514.
27.
Mai M, Tönjes A, Kovacs P, Stumvoll M, Fiedler GM, Leichtle AB. Serum levels of acylcarnitines are altered in prediabetic conditions. PLoS One 2013; 8: e82459.
28.
Panyard DJ, McKetney J, Deming YK, et al. Large-scale proteome and metabolome analysis of CSF implicates altered glucose and carbon metabolism and succinylcarnitine in Alzheimer’s disease. Alzheimer’s Dementia 2023; 19: 5447-70.
29.
Taylor K, McBride N, Zhao J, et al. The relationship of maternal gestational mass spectrometry-derived metabolites with offspring congenital heart disease: results from multivariable and mendelian randomization analyses. J Cardiovasc Dev Dis 2022; 9: 237.
30.
Starek-Świechowicz B, Budziszewska B, Starek A. Endogenous estrogens-breast cancer and chemoprevention. Pharmacol Rep 2021; 73: 1497-512.
31.
Tao T, He T, Mao H, Wu X, Liu X. Non-targeted metabolomic profiling of coronary heart disease patients with taohong siwu decoction treatment. Front Pharmacol 2020; 11: 651.
32.
Kim S, Lee MS, Kim M, et al. Derivatization-assisted LC-MS/MS method for simultaneous quantification of endogenous gamma-hydroxybutyric acid and its metabolic precursors and products in human urine. Anal Chim Acta 2022; 1194: 339401.
33.
Steuer AE, Raeber J, Steuer C, et al. Identification of new urinary gamma-hydroxybutyric acid markers applying untargeted metabolomics analysis following placebo-controlled administration to humans. Drug Test Anal 2019; 11: 813-23.
Share
RELATED ARTICLE
| eISSN: | 1896-9151 |
| ISSN: | 1734-1922 |
We process personal data collected when visiting the website. The function of obtaining information about users and their behavior is carried out by voluntarily entered information in forms and saving cookies in end devices. Data, including cookies, are used to provide services, improve the user experience and to analyze the traffic in accordance with the Privacy policy. Data are also collected and processed by Google Analytics tool (more).
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
